Gilead Sciences, Inc. GILD

Company Overview

Gilead Sciences, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for life-threatening diseases. The company primarily operates in the biotechnology and pharmaceutical industries, with major therapeutic focus areas including HIV/AIDS, viral hepatitis, oncology, and inflammatory diseases. Gilead’s revenue base is heavily driven by its HIV portfolio, which includes long-acting and oral antiretroviral therapies marketed globally. The company also generates significant revenue from oncology products and antiviral therapies for liver diseases and COVID-19.

Gilead’s core business lines include antiviral therapeutics, cell therapies, and oncology medicines. Key commercial products include Biktarvy, Descovy, Genvoya, Veklury (remdesivir), Trodelvy, and Yescarta. The company serves hospitals, specialty clinics, government health systems, and retail and specialty pharmacies across developed and emerging markets. Gilead is recognized for its leadership in HIV treatment and prevention, supported by extensive intellectual property, long-term clinical development programs, and established global distribution capabilities. Founded in 1987 and headquartered in Foster City, California, Gilead evolved from an antiviral-focused biotechnology company into a diversified biopharmaceutical enterprise through internal research and major acquisitions, including Kite Pharma and Immunomedics.